RARE (Ultragenyx Pharmaceutical) Cash per Share: $2.96 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

RARE Ultragenyx Pharmaceutical Inc RARE
69 GF Score
Price $26.24
GF Value $45.07
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is Ultragenyx Pharmaceutical Cash per Share?

Ultragenyx Pharmaceutical RARE +2.94% 69 Cash per Share is $2.96 as of Jun. 2026. GuruFocus rates RARE with a GF Score™ of 69/100 and a GF Value™ of $45.07 (Possible Value Trap). The stock has 5 warning signs investors should review.

Cash per Share is calculated as Cash, Cash Equivalents, Marketable Securities divided by Shares Outstanding (EOP). Ultragenyx Pharmaceutical's Cash per Share for the quarter that ended in Jun. 2026 was $2.96.

Ultragenyx Pharmaceutical  (NAS:RARE) Cash per Share Explanation

Cash per Share represents the liquidity of a compant's assets. A high level of Cash per Share suggests that there's enough money on hand for a company to cover any emergencies and that the company has adequate money to reinvest its business or pay dividends to investors. However, if the ratio is too high, it can also suggeust the inefficiency of management for not making a full usage of the cash.

Ultragenyx Pharmaceutical Cash per Share Related Terms

Ultragenyx Pharmaceutical Cash per Share Historical Data

* Premium members only.

The historical data trend for Ultragenyx Pharmaceutical's Cash per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ultragenyx Pharmaceutical Cash per Share Chart

Ultragenyx Pharmaceutical Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cash per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 10.67 10.65 7.01 6.60 7.05

Ultragenyx Pharmaceutical Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cash per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.95 4.41 7.05 4.20 2.96
RARE
69GF Score
Ultragenyx Pharmaceutical Inc RARE
Cash per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Ultragenyx Pharmaceutical Cash per Share Calculation

This is the ratio of a company's available cash, including easy to liquidate short-term investment, to its total number of shares outstanding. The result indicates the percentage of a company's share price that is available to spend on company's activities, such as strengthening the business, paying down the debt and making dividend payment to shareholders. It's a reliable indicator of a company's financial health.

Ultragenyx Pharmaceutical's Cash per Share for the fiscal year that ended in Dec. 2025 is calculated as:

Cash per Share= Cash, Cash Equivalents, Marketable Securities /Shares Outstanding (EOP)
=680/96.5
=7.05

Ultragenyx Pharmaceutical's Cash per Share for the quarter that ended in Jun. 2026 is calculated as:

Cash per Share= Cash, Cash Equivalents, Marketable Securities /Shares Outstanding (EOP)
=292/98.6
=2.96

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Cash per Share →
What does a Cash per Share of $2.96 mean?
Ultragenyx Pharmaceutical (RARE) has a Cash per Share of $2.96 as of Jun. 2026. Cash per share is the per-share value of a company's available cash. View historical data for Ultragenyx Pharmaceutical and its competitors.
Is Ultragenyx Pharmaceutical's Cash per Share too high?
Ultragenyx Pharmaceutical's current Cash per Share is $2.96. Overall, Ultragenyx Pharmaceutical has a GF Score™ of 69/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Ultragenyx Pharmaceutical's Cash per Share compare to ATAI and QURE?
Ultragenyx Pharmaceutical's Cash per Share of $2.96 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash per Share for a Biotechnology company?
A good Cash per Share depends on the Biotechnology industry context. However, Cash per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash per Share mean?
A high Cash per Share can signal that a stock is expensive relative to its fundamentals. Cash per share is the per-share value of a company's available cash. View historical data for Ultragenyx Pharmaceutical and its competitors. Ultragenyx Pharmaceutical's current Cash per Share is $2.96. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ultragenyx Pharmaceutical stock overvalued right now?
Based on GuruFocus' analysis, Ultragenyx Pharmaceutical (RARE) is currently considered Possible Value Trap. The stock's GF Value™ is $45.07, compared to a current price of $26.24 — trading 41.8% below its estimated fair value. The current Cash per Share is $2.96. Ultragenyx Pharmaceutical's overall GF Score™ is 69/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash per Share calculated?
Cash per Share is calculated from a company's financial statements. For Ultragenyx Pharmaceutical (RARE), the current Cash per Share is $2.96 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Ultragenyx Pharmaceutical (RARE) Overvalued in 2026?

Based on GuruFocus' analysis, Ultragenyx Pharmaceutical stock appears to be undervalued. The current stock price of $26.24 is trading 41.8% below its estimated GF Value™ of $45.07. GuruFocus considers Ultragenyx Pharmaceutical to be Possible Value Trap.

Key valuation signals for RARE:

  • Cash per Share: $2.96
  • GF Value™: $45.07 vs. price of $26.24 (41.8% below fair value)
  • GF Score™: 69/100 with 5 warning signs

No single metric tells the full story. See the RARE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Ultragenyx Pharmaceutical Business Description

Address 60 Leveroni Court, Novato, CA, USA, 94949
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. The company identifies, acquires, develops, and commercializes novel products for the treatment of serious, rare, and ultra-rare diseases, with a focus on debilitating genetic conditions. Its medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients aged one year and older. Mepsevii is indicated for pediatric and adult patients for the treatment of Mucopolysaccharidosis VII. The company operates across North America, Latin America, Europe, the Middle East and Africa, and Asia-Pacific, with the majority of its revenue generated from North America.
69GF Score

Get the complete analysis for RARE

Cash per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$26.24
Price
$45.07
GF Value